Literature DB >> 4039192

Interaction of platelet factor 4 with human platelets.

A M Capitanio, S Niewiarowski, B Rucinski, G P Tuszynski, C S Cierniewski, D Hershock, E Kornecki.   

Abstract

Human washed resting platelets bound 125I-labeled platelet factor 4 in a reaction which was saturable and approached equilibrium within 15-30 min. Scatchard plot analysis of the binding isotherms suggested a single class of specific binding sites. Excess of unlabeled protein and low- and high-affinity heparin competed for platelet factor 4 binding sites on the platelet surface and caused a partial displacement of this molecule. Anti-platelet factor 4 Fab fragments caused inhibition of binding of 125I-platelet factor 4 to platelets. Most of the labeled platelet factor 4 which was bound to intact platelets was recovered in the Triton X-100-insoluble cytoskeletal fraction prepared from the same platelets after their stimulation by thrombin. The association with the cytoskeleton was inhibited by anti-platelet factor 4 Fab fragments and by low-affinity heparin. Anti-platelet factor 4 125I-labeled Fab fragments bound to resting platelets, and this binding was greatly increased following platelet stimulation with thrombin. This suggested that endogenously secreted platelet factor 4 also binds to the platelet surface. No significant binding to platelets of 125I-labeled beta-thromboglobulin and 125I-labeled anti-beta-thromboglobulin Fab fragments was observed. Fab fragments of monospecific anti-human platelet factor 4 antibody raised in rabbits inhibited platelet aggregation and secretion induced by low concentrations of thrombin. Fab fragments of anti-beta-thromboglobulin antibody had no inhibitory effect. We suggest that the binding of alpha-granule-derived platelet factor 4 to the specific sites on the surface of platelets may modulate platelet aggregation and secretion induced by low levels of platelet agonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039192     DOI: 10.1016/0304-4165(85)90033-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).

Authors:  Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

2.  Platelet Factor 4 Binds to Vascular Proteoglycans and Controls Both Growth Factor Activities and Platelet Activation.

Authors:  Megan S Lord; Bill Cheng; Brooke L Farrugia; Simon McCarthy; John M Whitelock
Journal:  J Biol Chem       Date:  2017-01-23       Impact factor: 5.157

3.  Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding.

Authors:  K H Mayo; E Ilyina; V Roongta; M Dundas; J Joseph; C K Lai; T Maione; T J Daly
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

4.  Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.

Authors:  A M Gewirtz; B Calabretta; B Rucinski; S Niewiarowski; W Y Xu
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Factors affecting dense and alpha-granule secretion from electropermeabilized human platelets: Ca(2+)-independent actions of phorbol ester and GTP gamma S.

Authors:  J R Coorssen; M M Davidson; R J Haslam
Journal:  Cell Regul       Date:  1990-12

6.  Mean platelet volume predicts outcome in patients with asymptomatic carotid artery disease.

Authors:  Florian J Mayer; Matthias Hoke; Martin Schillinger; Erich Minar; Itziar Arbesú; Renate Koppensteiner; Christine Mannhalter
Journal:  Eur J Clin Invest       Date:  2013-10-26       Impact factor: 4.686

7.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.